Search ANAB
ANAPTYSBIO, INC
Nasdaq · CIK 1370053
Last close48.53
Daily change-0.10 (-0.21%)
10 Years gain+328.21%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ANAB · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 0630
Fundamental
88.0Momentum
100.0Acceleration
100.0Confidence
85.0Annual Revenue11
Quarterly Revenue31
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality17.0 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics6.6 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 242.4605 percentage points.
Share count reductionDiluted share count declined 0.6991%.
Key Metrics
Revenue Growth TTM195.06%OK
Revenue CAGR 3Y183.58%OK
Gross Margin100%OK
Operating Margin-35.31%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y4.24%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-0.7%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $234.60M | $234.60M | $47.90M | $19.70M | $19.61M | 100% | 20.42% | 8.36% | n/a | 28.76M |
| 2025 FY Dec 31, 2024 | $91.28M | $91.28M | -$114.95M | -$135.34M | -$135.70M | 100% | -125.93% | -148.66% | n/a | 28.38M |
| 2025 FY Dec 31, 2023 | $17.16M | $17.16M | -$164.41M | -$120.80M | -$121.61M | 100% | -958.27% | -708.79% | n/a | 26.92M |
| 2024 FY Dec 31, 2022 | $10.29M | $10.29M | -$115.15M | -$73.59M | -$73.95M | 100% | -1,119.41% | -718.88% | n/a | 28.17M |
| 2023 FY Dec 31, 2021 | $63.18M | $63.18M | -$56.81M | -$45.92M | -$47.29M | 100% | -89.93% | -74.85% | n/a | 27.43M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $151.91M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-219515, 0001370053-25-000064 |
| Revenue Growth TTM | 195.06% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-219515, 0001370053-25-000064 |
| Revenue CAGR 3Y | 183.58% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-088290 |
| Revenue CAGR 5Y | 25.62% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-088290 |
| Gross Profit CAGR 3Y | 183.58% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-088290 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-219515, 0001370053-25-000064 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001193125-26-219515, 0001370053-25-000064 |
| Operating Margin | -35.31% | Operating Income / Revenue | OK | 0001193125-26-219515, 0001370053-25-000064 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-219515 |
| Current Ratio | 7.58x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $5.29 | Revenue / Diluted Shares | OK | 0001193125-26-219515, 0001370053-25-000064 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001193125-26-187044 |